Learn more about the Project "Posttranslational modifications of neuropilin-2 and their effects on progression and therapy resistance of malignant diseases".
Neuropilin-2 is involved in Cancer Progression and Therapy Resistance
Neuropilin-2 (NRP2) is expressed in human tumors (and cell lines derived thereof) and often correlates with advanced stages and/or poor prognosis. As a co-receptor for a variety of ligands including class 3 semaphorins, vascular endothelial growth factors (VEGFs) and other growth factors, NRP2 is involved in various signaling pathways thereby regulating diverse cellular functions. Depending on tumor type, cell surface expression of co-receptors and availability of ligands, NRP2 is involved in cancer cell survival, proliferation, invasion/migration, endocytosis, lymphangiogenesis, tumor growth, etc.
Neuropilin-2 is a Cell Surface Glycoprotein
NRP2 consists of a large extracellular, a single transmembrane and a short cytosolic domain of approximately 40 amino acids. NRP2´s ectodomain, containing two CUB (a1, a2), two FV/FVIII (b1, b2) and one MAM (c) domain, is important for ligand binding and interaction with other receptors. Like most cell surface proteins, NRP2 is extensively glycosylated. Recent reports describe N and O glycosylation of NRP2 as well as a unique form of posttranslational modification, namely polysialylation which is found on only few proteins. If and how the different glycoforms of NRP2 are involved in cancer progression and therapy resistance is currently under investigation.
Using cell culture, human tissue and mouse models we are working on elucidating the molecular mechanisms of NRP2 in cancer and aiming to uncover prognostic and/or predictive markers and to develop novel therapeutic strategies based on our findings.